BridgeBio Pharma Inc vs Jumia Technologies AG - ADR — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Jumia Technologies AG - ADR trades at $5.98 (market cap $719.58M). The key difference: BridgeBio Pharma Inc is far larger — about 22.7× Jumia Technologies AG - ADR's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| BBIO | JMIA | |
|---|---|---|
Market Cap | $16.36B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $14.60 |
52-Week Low | $47.29 | $5.69 |
Enterprise Value | $18.14B | $666.68M |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →